O	0	1	[
O	1	2	A
O	3	8	pilot
O	9	14	study
O	15	17	of
O	18	24	weekly
O	25	31	versus
O	32	33	3
O	33	34	-
O	34	38	week
B-intervention	39	48	docetaxel
I-intervention	49	51	in
I-intervention	52	63	combination
I-intervention	64	68	with
I-intervention	69	81	capecitabine
O	82	84	in
O	85	93	patients
O	94	98	with
O	99	112	anthracycline
O	112	113	-
O	113	123	pretreated
O	124	134	metastatic
O	135	141	breast
O	142	148	cancer
O	148	149	]
O	149	150	.

O	151	153	To
O	154	162	evaluate
O	163	166	the
O	167	175	efficacy
O	176	179	and
O	180	186	safety
O	187	189	of
O	190	196	weekly
O	197	199	or
O	200	201	3
O	201	202	-
O	202	206	week
O	207	216	docetaxel
O	217	219	in
O	220	231	combination
O	232	236	with
O	237	249	capecitabine
O	249	250	.

B-total-participants	251	253	83
B-eligibility	254	262	Patients
I-eligibility	263	267	with
I-eligibility	268	270	at
I-eligibility	271	276	least
I-eligibility	277	280	one
I-eligibility	281	291	measurable
I-eligibility	292	298	lesion
O	299	303	were
O	304	314	randomized
O	315	317	to
O	318	325	receive
O	326	329	the
O	330	339	treatment
O	340	344	arms
O	344	345	:
O	346	355	docetaxel
O	356	358	37
O	358	359	.
O	359	360	5
O	361	363	mg
O	363	364	/
O	364	365	m
O	365	366	(
O	366	367	2
O	367	368	)
O	369	371	on
O	372	376	days
O	377	378	1
O	379	382	and
O	383	384	8
O	384	385	,
O	386	390	oral
O	391	403	capecitabine
O	404	407	950
O	408	410	mg
O	410	411	/
O	411	412	m
O	412	413	(
O	413	414	2
O	414	415	)
O	416	421	twice
O	422	427	daily
O	428	430	on
O	431	435	days
O	436	437	1
O	437	438	-
O	438	440	14
O	441	442	(
O	442	447	Group
O	448	449	A
O	449	450	)
O	450	451	;
O	452	461	docetaxel
O	462	464	75
O	465	467	mg
O	467	468	/
O	468	469	m
O	469	470	(
O	470	471	2
O	471	472	)
O	473	475	on
O	476	480	days
O	481	482	1
O	482	483	,
O	484	488	oral
O	489	501	capecitabine
O	502	505	950
O	506	508	mg
O	508	509	/
O	509	510	m
O	510	511	(
O	511	512	2
O	512	513	)
O	514	519	twice
O	520	525	daily
O	526	528	on
O	529	533	days
O	534	535	1
O	535	536	-
O	536	538	14
O	539	540	(
B-control	540	545	Group
I-control	546	547	B
O	547	548	)
O	548	549	.

O	550	554	Each
O	555	560	cycle
O	561	564	was
O	565	573	repeated
O	574	579	every
O	580	581	3
O	582	587	weeks
O	587	588	.

B-total-participants	589	595	Eighty
I-total-participants	595	596	-
I-total-participants	596	601	three
O	602	610	patients
O	611	615	were
O	616	624	enrolled
O	624	625	,
B-total-participants	626	628	78
O	629	637	eligible
O	638	641	for
O	642	647	tumor
O	648	658	assessment
O	658	659	.

O	660	663	The
B-outcome	664	671	overall
I-outcome	672	680	clinical
I-outcome	681	689	response
I-outcome	690	694	rate
O	695	697	of
O	698	701	all
O	702	708	groups
O	709	712	was
O	713	715	61
O	715	716	.
O	716	717	4
O	717	718	%
O	719	720	(
O	720	722	51
O	722	723	/
O	723	725	83
O	725	726	)
O	726	727	.

O	728	733	There
O	734	737	was
O	738	740	no
B-outcome	741	752	progressive
I-outcome	753	760	disease
I-outcome	761	762	(
I-outcome	762	764	PD
I-outcome	764	765	)
O	766	771	after
O	772	775	two
O	776	782	cycles
O	782	783	.

B-outcome	784	792	Efficacy
I-outcome	793	801	outcomes
O	802	806	were
O	807	814	similar
O	815	817	in
O	818	821	the
O	822	825	two
O	826	832	groups
O	832	833	.

O	834	837	The
B-outcome	838	846	response
I-outcome	847	851	rate
O	852	854	of
O	855	860	group
O	861	862	A
O	863	866	and
O	867	868	B
O	869	873	were
B-iv-bin-percent	874	876	61
I-iv-bin-percent	876	877	.
I-iv-bin-percent	877	878	8
I-iv-bin-percent	878	879	%
O	880	881	(
B-iv-bin-abs	881	883	21
O	883	884	/
B-intervention-participants	884	886	34
O	886	887	)
O	888	891	and
B-cv-bin-percent	892	894	61
I-cv-bin-percent	894	895	.
I-cv-bin-percent	895	896	2
I-cv-bin-percent	896	897	%
O	898	899	(
B-cv-bin-abs	899	901	30
O	901	902	/
B-control-participants	902	904	49
O	904	905	)
O	906	918	respectively
O	918	919	.

O	920	925	There
O	926	930	were
O	931	933	no
B-outcome	934	938	drug
I-outcome	938	939	-
I-outcome	939	946	related
I-outcome	947	953	deaths
O	954	962	observed
O	962	963	.

B-outcome	964	975	Neutropenia
O	976	979	was
O	980	983	the
O	984	988	most
O	989	995	common
O	996	1004	toxicity
O	1004	1005	.

O	1006	1008	In
O	1009	1012	all
O	1012	1013	,
O	1014	1017	the
O	1018	1027	frequency
O	1028	1030	of
B-outcome	1031	1036	Grade
I-outcome	1037	1038	3
I-outcome	1038	1039	/
I-outcome	1039	1040	4
I-outcome	1041	1052	neutropenia
O	1053	1057	were
O	1058	1060	45
O	1060	1061	.
O	1061	1062	8
O	1062	1063	%
O	1064	1065	(
O	1065	1067	38
O	1067	1068	/
O	1068	1070	83
O	1070	1071	)
O	1071	1072	,
O	1073	1076	but
O	1077	1082	Grade
O	1083	1084	3
O	1084	1085	/
O	1085	1086	4
O	1087	1098	neutropenia
O	1099	1101	of
O	1102	1107	Group
O	1108	1109	B
B-cv-bin-percent	1110	1112	55
I-cv-bin-percent	1112	1113	.
I-cv-bin-percent	1113	1114	1
I-cv-bin-percent	1114	1115	%
O	1116	1117	(
B-cv-bin-abs	1117	1119	27
O	1119	1120	/
B-control-participants	1120	1122	49
O	1122	1123	)
O	1124	1127	was
O	1128	1134	higher
O	1135	1139	than
O	1140	1145	Group
O	1146	1147	A
B-iv-bin-percent	1148	1150	32
I-iv-bin-percent	1150	1151	.
I-iv-bin-percent	1151	1152	4
I-iv-bin-percent	1152	1153	%
O	1154	1155	(
B-iv-bin-abs	1155	1157	11
O	1157	1158	/
B-intervention-participants	1158	1160	34
O	1160	1161	)
O	1161	1162	,
O	1163	1164	P
O	1165	1166	=
O	1167	1168	0
O	1168	1169	.
O	1169	1171	04
O	1171	1172	.

O	1173	1176	The
O	1177	1182	study
O	1183	1192	confirmed
O	1193	1196	the
O	1197	1205	superior
O	1206	1214	activity
O	1215	1217	of
O	1218	1226	docetaxe
O	1226	1227	-
O	1227	1239	capecitabine
O	1240	1251	combination
O	1252	1259	therapy
O	1260	1262	in
O	1263	1276	anthracycline
O	1277	1286	resistant
O	1287	1290	MBC
O	1290	1291	,
O	1292	1295	and
O	1296	1305	comparing
O	1306	1310	with
O	1311	1312	3
O	1312	1313	-
O	1313	1317	week
O	1318	1326	schedule
O	1326	1327	,
O	1328	1334	weekly
O	1335	1344	docetaxel
O	1345	1349	plus
O	1350	1362	capecitabine
O	1363	1366	has
O	1367	1371	same
O	1372	1376	high
O	1377	1385	efficacy
O	1386	1390	with
O	1391	1392	a
O	1393	1403	favourable
O	1404	1410	safety
O	1411	1418	profile
O	1418	1419	.
